A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.

Author: LecrenierNicolas, ParikhRaunak, WidenmaierRobyn

Paper Details 
Original Abstract of the Article :
The adjuvanted recombinant zoster vaccine (RZV) is currently licensed in over 30 countries for the prevention of herpes zoster (HZ) in adults aged ≥50 years. We conducted a review of available national guidelines or recommendations on RZV use to identify the similarities and differences and highligh...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1080/14760584.2021.1956906

データ提供:米国国立医学図書館(NLM)

A Guide to the Recombinant Zoster Vaccine: A New Oasis in the Desert of Herpes Zoster

This study reviews available [national guidelines and recommendations] on the use of the adjuvanted recombinant zoster vaccine (RZV) for preventing [herpes zoster (HZ)] in adults aged 50 years and older. The researchers analyzed various national guidelines, identifying similarities and differences, and highlighting potential gaps in current recommendations. The study underscores the importance of widespread vaccination against HZ and advocates for continued efforts to optimize vaccination strategies.

Protecting Against Herpes Zoster: A Vaccination Strategy

Herpes zoster, also known as shingles, can be a painful and debilitating condition, often leaving individuals with lingering discomfort and complications. This study emphasizes the importance of vaccination against HZ, particularly for adults aged 50 years and older, who are at increased risk for developing this condition. The findings highlight the need for continued efforts to promote widespread vaccination and optimize vaccination strategies to protect individuals from the devastating effects of HZ.

Fighting the Desert of Shingles: The Power of Vaccination

Imagine a desert where the sun's harsh rays can cause painful and debilitating blisters. This analogy reflects the challenges faced by individuals suffering from herpes zoster, commonly known as shingles. The adjuvanted recombinant zoster vaccine (RZV) offers a valuable tool for preventing this painful condition, acting as a protective oasis in the desert of shingles. This study emphasizes the importance of vaccination for adults aged 50 years and older, who are at increased risk for developing this condition. The findings highlight the crucial role of vaccination in protecting individuals from the debilitating effects of HZ, promoting overall health and well-being.

Dr.Camel's Conclusion

This study provides a valuable guide to the recombinant zoster vaccine, emphasizing its importance for preventing herpes zoster in adults aged 50 years and older. The findings highlight the need for continued efforts to promote widespread vaccination and optimize vaccination strategies to protect individuals from this painful and potentially debilitating condition.

Date :
  1. Date Completed 2022-04-01
  2. Date Revised 2022-04-26
Further Info :

Pubmed ID

34311643

DOI: Digital Object Identifier

10.1080/14760584.2021.1956906

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.